TEAD Inhibitors Sensitize KRAS<sup>G12C</sup> Inhibitors via Dual Cell Cycle Arrest in KRAS<sup>G12C</sup>-Mutant NSCLC
KRAS<sup>G12C</sup> is one of the most common mutations detected in non-small cell lung cancer (NSCLC) patients, and it is a marker of poor prognosis. The first FDA-approved KRAS<sup>G12C</sup> inhibitors, sotorasib and adagrasib, have been an enormous breakthrough for patien...
Saved in:
Main Authors: | Salvina Laura Tammaccaro (Author), Philippe Prigent (Author), Jean-Christophe Le Bail (Author), Odette Dos-Santos (Author), Laurent Dassencourt (Author), Myriam Eskandar (Author), Armelle Buzy (Author), Olivier Venier (Author), Jean-Claude Guillemot (Author), Yaligara Veeranagouda (Author), Michel Didier (Author), Emmanuel Spanakis (Author), Tokuwa Kanno (Author), Matteo Cesaroni (Author), Stephane Mathieu (Author), Luc Canard (Author), Alhassan Casse (Author), Fanny Windenberger (Author), Loreley Calvet (Author), Laurence Noblet (Author), Sukhvinder Sidhu (Author), Laurent Debussche (Author), Jurgen Moll (Author), Iris Valtingojer (Author) |
---|---|
Format: | Book |
Published: |
MDPI AG,
2023-04-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Virtual Screening Based on Machine Learning Explores Mangrove Natural Products as KRAS<sup>G12C</sup> Inhibitors
by: Lianxiang Luo, et al.
Published: (2022) -
Nuclear Cross-Section of Proton-Induced Reactions on Enriched <sup>48</sup>Ti Targets for the Production of Theranostic <sup>47</sup>Sc Radionuclide, <sup>46c</sup>Sc, <sup>44m</sup>Sc, <sup>44g</sup>Sc, <sup>43</sup>Sc, and <sup>48</sup>V
by: Liliana Mou, et al.
Published: (2023) -
Comparing Salivary Caffeine Kinetics of <sup>13</sup>C and <sup>12</sup>C Caffeine for Gastric Emptying of 50 mL Water
by: Michael Grimm, et al.
Published: (2023) -
Target Development towards First Production of High-Molar- Activity <sup>44g</sup>Sc and <sup>47</sup>Sc by Mass Separation at CERN-MEDICIS
by: Edgars Mamis, et al.
Published: (2024) -
Radioligand Therapy with [<sup>177</sup>Lu]Lu-DOTA-TATE or [<sup>177</sup>Lu]Lu-DOTA-TATE and [<sup>90</sup>Y]Y-DOTA-TATE in Patients with Neuroendocrine Neoplasms of Unknown Locations, or Locations Other Than the Midgut and Pancreas as Primaries in a G1, G2 and G3 Grade
by: Adam Daniel Durma, et al.
Published: (2023)